We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,544

What the Supreme Court of Canada was not told about patent utility
  • Gowling WLG
  • Canada
  • May 11 2017

On November 8, 2016 the Supreme Court of Canada (“SCC”) heard an appeal by Astrazeneca regarding the validity of a patent covering its NEXIUM product


Bill C-30 passes Senate today to usher in changes to Canadian pharma patent regulations
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • May 11 2017

Bill C-30 was passed by the Senate today, May 11, 2017 without amendment. Bill C-30 is the bill that will implement the Canada-European Union


Update on implementing CETA in Canada - What pharmaceutical companies need to know
  • Marks & Clerk
  • Canada, European Union
  • May 10 2017

The Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union was approved by all 28 EU member states in October 2016


That's a wrap: Springboard profits, full cost accounting, and more from the Federal Court in Dow v. Nova
  • Gowling WLG
  • Canada
  • May 11 2017

In a recent decision (Dow Chemical Co. v. Nova Chemicals Corp, 2017 FC 350) the Federal Court has addressed an assortment of issues that can arise


Court dismisses motion for Confidentiality Order
  • Borden Ladner Gervais LLP
  • Canada
  • May 18 2017

The Court dismissed Teva's motion for a confidentiality order. The underlying proceeding is an action by Teva to recover from Janssen and others


The Pricing of Patented Drugs in Canada: Stakeholder Consultation Period Open Until June 28, 2017
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • May 17 2017

The Patented Medicine Prices Review Board (PMPRB) regulates the price of Patented medicines in Canada by determining whether a price is excessive


CIALIS Patent Survives Validity Challenge on Appeal
  • McCarthy Tétrault LLP
  • Canada
  • May 19 2016

Last year we wrote about a trilogy of Federal Court decisions relating to Eli Lilly’s erectile dysfunction (ED) drug CIALIS (tadalafil). While Lilly


Competitionantitrust law
  • Dentons
  • China, European Union, Germany, OECD, United Kingdom, USA, Australia, Canada
  • February 9 2017

In the wake of the 2016 elections, we now await the decision as to who will be the "antitrust guard" at the top of the US Department


International Trade Compliance Update - September 2016
  • Baker McKenzie
  • United Kingdom, USA, Australia, Canada, European Union
  • September 7 2016

On 19 August 2016, the Russian Federation notified the WTO that it intends to initiate negotiations pursuant to Paragraph 1143 of the Working Party


Canadian Court of Appeal has Something to Say on Obviousness: Critical of Rigid Tests and Using a Solution-Based Identification of the Inventive Concept that Excludes Serendipitous Discoveries Means Atazanavir Salt Obvious
  • Aird & Berlis LLP | Aird & McBurney LP
  • Canada
  • May 8 2017

The Federal Court of Appeal ("FCA") recently affirmed a Federal Court ("FC") finding that an antiviral salt was obvious, although based on different